BREXPIPRAZOLE
Total Payments
$3.4M
Transactions
397
Doctors
66
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $59,088 | 55 | 19 |
| 2017 | $3.3M | 342 | 52 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 320 | 98.0% |
| Consulting Fee | $46,033 | 27 | 1.4% |
| Travel and Lodging | $21,135 | 31 | 0.6% |
| Food and Beverage | $894.23 | 15 | 0.0% |
| Education | $711.92 | 2 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118.98 | 2 | 0.0% |
Payments by Type
Research
$3.3M
320 transactions
General
$68,894
77 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $965,567 | 8 |
| SAFETY AND TOLERABILITY STUDY OF FLEXIBLE DOSING OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $917,347 | 2 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BREXPIPRAZOLE PLUS KETAMINE IN TREATMENT-RESISTANT DEPRESSION TRD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $874,859 | 0 |
| A STUDY OF FLEXIBLE-DOSE BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $312,494 | 1 |
| SAFETY FOLLOW-UP STUDY FOR SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE WHO PREVIOUSLY PARTICIPATED IN A DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE OR PLACEBO | Otsuka Pharmaceutical Development & Commercialization, Inc. | $105,803 | 3 |
| BREXPIPRAZOLE FOR BIPOLAR DEPRESSION | Otsuka Pharmaceutical Development & Commercialization, Inc. | $83,301 | 0 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial | Otsuka Pharmaceutical Development & Commercialization, Inc. | $37,466 | 32 |
| A 2-MONTH, OBSERVATIONAL, ROLLOVER TRIAL TO EVALUATE THE SAFETY OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE WHO WERE PREVIOUSLY TREATED WITH BREXPIPRAZOLE OPC-34712 OR PLACEBO IN A PHASE 3, DOUBLE-BLIND TRIAL | Otsuka Pharmaceutical Development & Commercialization, Inc. | $975.76 | 0 |
Top Doctors Receiving Payments for BREXPIPRAZOLE — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Psychiatry | Long Beach, CA | $1,017 | 5 |
| George Joseph | — | Jacksonville Beach, FL | $1,000 | 1 |
| , M.D | Psychiatry | Rockville, MD | $1,000 | 2 |
| Isak Isakov | Psychiatry | Forest Hills, NY | $914.12 | 5 |
| , MD | Addiction Medicine | Houston, TX | $900.00 | 1 |
| , MD | Psychiatry | San Diego, CA | $887.27 | 5 |
| , M.D | Psychiatry | Oklahoma City, OK | $739.34 | 4 |
| , MD | Psychiatry | Cleveland, OH | $700.00 | 1 |
| , M.D | Psychiatry | Wichita Falls, TX | $637.28 | 3 |
| , MD | Neurology | Phoenix, AZ | $509.62 | 2 |
| , MD | Psychiatry | Cincinnati, OH | $375.00 | 1 |
| , MD | Psychiatry | Boston, MA | $328.00 | 1 |
| , MD | Forensic Psychiatry | Boston, MA | $300.00 | 1 |
| , MD | General Practice | Rochester, NY | $178.40 | 3 |
| , MD | Psychiatry | Coral Gables, FL | $158.21 | 3 |
| , M.D | Psychiatry | Miami, FL | $158.21 | 3 |
| , M.D | Psychiatry | Durham, NC | $87.25 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.4M
- Total Doctors 66
- Transactions 397
About BREXPIPRAZOLE
BREXPIPRAZOLE is a drug associated with $3.4M in payments to 66 healthcare providers, recorded across 397 transactions in the CMS Open Payments database. The primary manufacturer is Otsuka Pharmaceutical Development & Commercialization, Inc..
Payment data is available from 2017 to 2018. In 2018, $59,088 was paid across 55 transactions to 19 doctors.
The most common payment nature for BREXPIPRAZOLE is "Unspecified" ($3.3M, 98.0% of total).
BREXPIPRAZOLE is associated with 8 research studies, including "A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE" ($965,567).